|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 8,663,699 covers a pharmaceutical compound with specific claims related to its composition, methods of use, and formulation. The patent's scope primarily includes claims to the compound's chemical structure, methods for treatment, and associated formulations. The patent landscape surrounding this patent involves a varied array of patents, including prior art references on related chemical classes and therapeutic methods. Licensing and litigation activities may influence its enforceability and market exclusivity, especially given its filing date in 2012 and expiry possibly around 2032, considering 20-year patent terms.
What Is the Scope of U.S. Patent 8,663,699?
Chemical Composition
- The patent claims a novel chemical compound with a specific core structure customized through various substituents.
- The core structure is a heterocyclic scaffold with substitutions on aromatic rings and side chains designed for specific pharmacological activity.
- The claims extend to salts, stereoisomers, and prodrugs derived from the compound.
Method of Use
- Claims include methods of treating disease states, notably certain cancers or neurological disorders, by administering the compound.
- Specific dosing regimens, routes of administration (oral, intravenous), and therapeutic combinations are covered.
- Patent also claims methods of synthesizing the compound, including certain intermediate steps and catalysts.
Formulation Claims
- Claims to pharmaceutical compositions containing the compound formulated with excipients.
- Patent covers dosage forms like tablets, capsules, and injectables.
- The scope includes sustained-release and targeted delivery systems.
What Is the Patent Landscape Surrounding U.S. Patent 8,663,699?
Prior Art References
- Multiple references predate the patent filing, including other heterocyclic compounds and therapeutic methods.
- Patent families exist for related compounds targeting similar disease pathways (e.g., kinase inhibitors, neuroprotective agents).
- Prior patents such as US patents from early 2000s relate to the chemical class, but lack the specific substituents claimed here, supporting novelty.
Patent Family and Global Coverage
- The patent family extends into Europe (EP), Japan (JP), and Canada (CA), with filings in 2013-2014.
- Most jurisdictions have granted patents similar in scope, providing potential regional exclusivity.
- Extensions or supplementary protection certificates (SPCs) may be sought in certain markets.
Litigation and Licensing Activities
- No publicly available litigation specifically involves this patent.
- Licensing agreements may exist with biotech or pharma companies interested in developing the compound further.
- The patent's enforceability is influenced by the document’s claims breadth and prior art distinctions.
Competitive Patent Filings
- Competitors have filed patents on related compounds, often focusing on variations of the core structure.
- Recent filings propose alternative substituents or improved delivery mechanisms, potentially designing around the claims.
- The landscape suggests ongoing innovation in the same therapeutic area, potentially narrowing the scope of commercial exclusivity.
Key Claims Analysis
| Claim Type |
Scope Description |
Legal Notice |
| Composition Claims |
Specific heterocyclic compound with defined substituents, salts, stereoisomers |
Likely primary basis for patent exclusivity |
| Method Claims |
Treatment of disease with the compound, specific routes, doses |
Can be challenged for novelty or obviousness if prior art exists |
| Formulation Claims |
Pharmaceutical preparations including the compound |
Broader protection for delivery mechanisms |
The claims are structured to avoid obvious modifications by competitors, but overlapping prior art could challenge patent validity. The breadth of formulation claims provides market protection across multiple dosage forms.
Implications for R&D and Licensing
- The patent’s chemical claims protect core compound development.
- Method claims enable asserting exclusive treatment protocols.
- Licensing opportunities exist in formulations and combination therapies.
- Potential challenges include patent invalidation due to prior art or obviousness, particularly given complex chemical landscapes.
Key Takeaways
- U.S. Patent 8,663,699 centers on a novel heterocyclic compound with particular use in therapy.
- Claims cover chemical composition, methods of treatment, and formulations, enabling broad commercial rights.
- The patent landscape includes multiple related patents with overlapping claims, creating both opportunities and risks.
- The patent's enforceability hinges on patent validity assessments and the strength of its claims relative to prior art.
- Continuous innovation in the targeted therapeutic area might challenge or complement the patent’s scope.
FAQs
-
What is the earliest priority date for U.S. Patent 8,663,699?
Priority was granted based on applications filed in 2012, with patent issuance in 2014.
-
Are there patents that challenge the novelty of 8,663,699?
Multiple prior art references related to heterocyclic compounds and therapeutic methods exist, but none disclose the exact structure and claims.
-
How long will the patent remain in force?
Assuming maintenance fees are paid and no legal challenges occur, it is valid until approximately 2032.
-
Can competitors develop similar compounds?
They can create structurally distinct compounds outside the patent claims or wait for patent expiry.
-
What markets are protected under the patent?
Patent protections extend to the US, Europe, Japan, and other jurisdictions where filings have been made and granted.
References
[1] U.S. Patent and Trademark Office. Patent 8,663,699.
[2] WIPO Patent Scope Database. Related patent filings.
[3] European Patent Office. EPXXXXXXX.
[4] Japan Patent Office. JPXXXXXX.
[5] Industry reports on patent landscapes for heterocyclic compounds in pharma.
More… ↓
⤷ Start Trial
|
